Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domatinostat and Sirolimus in Relapsed/Refractory Sarcoma and Osteosarcoma
NCT07725380Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Jul 2026
- Primary completion
- Aug 2031
- Countries
- 1
01
Overview
Phase 2, open-label trial of Domatinostat in sarcoma and osteosarcoma (OS) (3 arms), sponsored by Moffitt Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and Event-Free Survival at 4 months. Started Jul 2026; status: recruiting.
02
Drugs
Domatinostat
03
Conditions
sarcomaosteosarcoma (OS)
Beyond the preview
Go deeper on NCT07725380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07725380.